TrialPath
Recruiting

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

NCT06671613 · VA Office of Research and Development
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer
About this study
Cancer cells use an increased supply of glucose to make energy and do not have protection against fasting that normal cells do. Because of this, researchers would like to study how fasting may help immunotherapy target cancer cells. Initial studies suggest that fasting may decrease the side effects of immunotherapy and increase the chances of your cancer responding to the immunotherapy. Patient populations will have non-small cell lung cancer in which pembrolizumab have been recommended to treat the cancer as part of standard care
Eligibility criteria
Inclusion Criteria: * 18 years at the time of informed consent * Ability to provide written informed consent and HIPAA authorization. * Eastern cooperative group (ECOG) performance status of 0 to 2 * Newly diagnosed histologically or cytologically confirmed stage IV Non-Small Cell Lung Cancer (NSCLC). Patients with locally advanced NSCLC that are not candidates for definitive therapy but are candidates for trial are allowed per investigator discretion. * BMI 19 kg/m2 * Patients should be enrolled prior to starting standard of care immunotherapy for the treatment of stage IV NSCLC. Patients should be on PD (L)1 inhibitor alone (i.e., with PD-L1 expression 50%) in the metastatic setting. The investigators will allow single agent pembrolizumab only as the checkpoint inhibitor. * Patients requiring palliative radiation or definitive radiation to an oligometastatic disease prior to the initiation of single agent checkpoint inhibitors are allowed once radiation has been completed and patients have recovered from toxicities. Exclusion Criteria: * Self-reported weight loss of \> 10% in the 6 weeks prior to study entry * History of symptomatic hypoglycemia or uncontrolled diabetes * Prior therapies with inhibitors of insulin growth factor I(IGF-1) such as Linsitinib or Picropodophyllin * Concurrent use of somatostatin * Concurrent use of immunosuppressive medications including sirolimus, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, dexamethasone, or cyclosporine * Significant food allergies which would make the subject unable to consume the food provided. * History or current evidence of any uncontrolled medical or psychiatric condition, therapy that may confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the participating subject as deemed by the treating investigator. * Pregnant or lactating females are not eligible.
Study design
Enrollment target: 66 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-10-27
Estimated completion: 2030-12-31
Last updated: 2026-11-19
Interventions
Dietary Supplement: FMDCombination Product: Regular Diet Plus FMD
Primary outcomes
  • • Feasibility of fasting mimicking diet intervention (Through study completion up to 2 years.)
  • • Compliance (Through study completion up to 2 years.)
Sponsor
VA Office of Research and Development · fed
With: Indiana University, US Department of Veterans Affairs Cooperative Studies Program, L-Nutra Inc
Contacts & investigators
ContactShadia Jalal, MD · contact · Shadia.Jalal@va.gov · (317) 274-5500
ContactAleksandra Radovanovich, RN · contact · aleksandra.radovanovich@va.gov · (317) 988-3338
InvestigatorShadia Jalal, MD · principal_investigator, Richard L. Roudebush VA Medical Center, Indianapolis, IN
All locations (4)
VA Long Beach Healthcare System, Long Beach, CARecruiting
Long Beach, California, United States
Jesse Brown VA Medical Center, Chicago, ILRecruiting
Chicago, Illinois, United States
Richard L. Roudebush VA Medical Center, Indianapolis, INRecruiting
Indianapolis, Indiana, United States
St. Louis VA Medical Center John Cochran Division, St. Louis, MORecruiting
St Louis, Missouri, United States
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · TrialPath